<DOC>
	<DOCNO>NCT02869074</DOCNO>
	<brief_summary>The present Project third phase previous PCM-EVW-ES Project ( Batlle et al . Thromb &amp; Haemost 2015 ) aim extension , analysis innovation development field von Willebrand disease ( VWD ) base newer recently available methodology . The aim project help physician uniform characterization therapy VWD clinical practice , international level . A reduction expense diagnosis process use new methodology pursue .</brief_summary>
	<brief_title>Molecular Clinical Profile Von Willebrand Disease Spain</brief_title>
	<detailed_description>The present Project third phase previous PCM-EVW-ES Project ( Batlle et al . Thromb &amp; Haemost 2015 ) aim extension , analysis innovation development field von Willebrand disease ( VWD ) base newer recently available methodology . The aim project help physician uniform characterization therapy VWD clinical practice , international level . A reduction expense diagnosis process use new methodology pursue . The specific objective correspond task present project follow : 1 . Extension central phenotypic next generation sequencing ( NGS ) genotypic characterization VWD Spain , prospective recruitment Spanish VWD cohort approximately 500 new patient local historical VWD diagnosis ( approximately 38 centre ) . . Improvement registry portal database . ii . Recruitment criterion , phenotypic genetic analysis new recruit patient . In silico study novel von Willebrand factor gene ( VWF ) mutation iii . Analysis/investigation potential interrelationship different clinical , phenotypic genetic variation recruit patient . iv . Validation/confirmation PCM-EVW-ES new initial diagnostic propose algorithm include VWF NGS analysis . This project involve lead innovation translational research direct impact quality clinical care ( applicability ) . To knowledge similar project field . Potential patent may derive project . It involve also development e-learning new information technology ( debate forum , ad , google search engine ) . This project may promote international collaboration . Development algorithmic platform facilitate diagnosis therapy orientation VWD clinical practice use select data overwhelm amount information new technology , NGS , produce .</detailed_description>
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<criteria>One following : 1 . VWF ≤ 30 IU/d , 2 occasion . 2 . Presence multimeric abnormality . 3 . If isolate FVIII deficiency demonstration decrease FVIII binding . 4 . Presence VWF mutation . 5 . ↑ RIPA low concentration ristocetin . 1 . Presence data suggest AVWS . 2 . Absence sign patient inform consent</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>von Willebrand disease ( VWD )</keyword>
	<keyword>von Willebrand factor ( VWF )</keyword>
	<keyword>von Willebrand factor gene</keyword>
	<keyword>next generation sequence</keyword>
	<keyword>diagnosis</keyword>
	<keyword>VWD Spanish Cohort</keyword>
</DOC>